FDA approves first adenoviral vector-based gene therapy for high-risk Bacillus Calmette-Gu érin unresponsive non-muscle invasive bladder cancer

FDA approves first adenoviral vector-based gene therapy for high-risk Bacillus Calmette-Gu érin unresponsive non-muscle invasive bladder cancer
Source: FDA Center for Drug Evaluation and Research - What's New - Category: Drugs & Pharmacology Authors: Source Type: news